LOGIN  |  REGISTER
Chimerix
Amneal Pharmaceuticals

Azenta Announces Fiscal 2023 Second Quarter Earnings Conference Call and Webcast

May 03, 2023 | Last Trade: US$47.81 0.55 1.16

BURLINGTON, Mass., May 3, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2023 earnings which ended on March 31, 2023 on Tuesday, May 9, 2023 after the market closes.

The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday May 9, 2023, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-9761 for domestic callers and +1-212-231-2919 for international callers.

Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 10, 2023.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS: 
Sara Silverman 
Head of Investor Relations & Corporate Communications 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Sherry Dinsmore 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Azenta logo (PRNewsfoto/Azenta)

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB